ERBB2 and breast cancer: Notably, the NeoSphere trial randomized 417 patients with HER2-positive breast cancer to four treatment arms, docetaxel plus trastuzumab, docetaxel plus trastuzumab and pertuzumab (THP), trastuzumab plus pertuzumab (HP), and docetaxel plus pertuzumab.